Trial Profile

Expanded Access Program of Odevixibat (Bylvay) for the Treatment of Alagille syndrome patients

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odevixibat (Primary)
Indications Alagille syndrome
Focus Expanded access; Therapeutic Use
Sponsors Albireo Pharma

Most Recent Events

04 Apr 2022 New trial record
29 Mar 2022 According to an Albireo Pharma media release, first patient has been enrolled.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com